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 87 ADHD patients were ERP-tested twice; test 2 on stimulant medication; followed by 4 weeks clin-
ical trial.
 After the trial they were classified as responders (REs) or non-responders (non-REs).
 REs and non-REs differed significantly in their single-dose responses on the P3no-go (d = 1.76), sug-
gesting utility of P3no-go ERP in predicting treatment response.
a b s t r a c t
Objective: Approximately 30% of children and adolescents diagnosed with attention-deficit/hyperactivity
disorder (ADHD) and treated with stimulants are considered non-responders (non-REs). Reliable predic-
tors of response are missing. We examined changes in Event-Related Potentials (ERPs) induced by a single
dose of stimulant medication in order to predict later clinical response.
Methods: ERPs were registered twice during performance of a visual cued go/no-go task in 87 ADHD
patients (27 girls) aged 8–18 years; the second recording on a single dose of stimulant medication, fol-
lowed by a systematic medication trial lasting 4 weeks. Based on the four-week trial, participants were
categorized as responders (REs, N = 62) or non-REs (N = 25). Changes among REs and non-REs in ERP com-
ponents (cueP3, CNV, P3go, N2no-go, P3no-go) and behavioral-test variables were then compared.
Results: REs and non-REs differed significantly in medication-induced changes in P3no-go, cue-P3, CNV,
omission errors, reaction time, and reaction-time variability. The largest effect size was found for P3no-go
amplitude (p < .001; d = 1.76). Changes in P3no-go and omission errors correctly classified 90% of the REs
and 76% of the non-REs, when controlling for the age of the participants.
Conclusion: Clinical response to stimulants can be predicted by assessing single-dose changes in the
P3no-go ERP component amplitude.
Significance: Changes in P3no-go may be a clinically useful marker of response to stimulants.
 2016 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Attention-deficit hyperactivity disorder (ADHD) is a common
developmental disorder involving problems with attention and/or
hyperactivity and impulsivity. It is typically identified in child-hood, with symptoms often persisting throughout adulthood
(Faraone et al., 2000). Comorbid disorders in behavior, emotion,
learning, and autism spectrum are common (Hermens et al.,
2006; American Psychiatric Association, 2013). Prevalence of
ADHD is approximately 3–7% in school-aged children (Willcutt,
2012; Paule et al., 2000) and is relatively consistent across class,
culture, and ethnic background (Polanczyk and Jensen, 2008;
Barkley, 2006). The influence of genetic factors is well documented
(Barkley, 2006; Nigg, 2005).
Medical treatments with psychostimulants like methylpheni-
date (MPH), dextroamphetamine (DEX), and the nonstimulant
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lants (reduced restlessness/hyperactivity, improved sustained
attention, reduction of impulsive acts), are reported in approxi-
mately 70% of patients (Greenhill et al., 2002; Hodgkins et al.,
2012; Parr et al., 2003; Pliszka, 2003; Spencer et al., 1996;
Ishii-Takahashi et al., 2015; Cho et al., 2007). A shift to DEX or
ATX for non-responders (non-REs) increases therapeutic effects
to 80% (Barkley, 2006). Numerous studies have implicated the
fronto-subcortical networks of the brain as a prime candidate for
the source of the underlying dysfunction; including hypofunction-
ing dopamine and noradrenalin systems (Hermens et al., 2005).
Psychostimulants seem to increase activation in the frontal
cortex and striatum (Volkow et al., 2012; Engert and Pruessner,
2008)—key areas of cognitive control—and may underlie the
positive clinical effects of stimulants (Rubia et al., 2014).
Early identification of non-REs is critical in order to avoid
long-term-ineffective medication trials and to ensure that other
treatment options (medical and/or psycho-social) are initiated.
The traditional approach has been to attempt to identify predictors
based on information collected before initiation of medication tri-
als. Despite these attempts, there is currently no reliable method
for predicting how patients will respond, without exposure to a
trial period of medication (Johnston et al., 2015). As effects of
MPH and DEX can often be observed on single doses, however,
another less frequent approach to predicting clinical response is
to examine effects of a single dose.
1.1. Predictors of stimulant medication response
Previous studies aimed at predicting treatment response to
medication have applied neuropsychological test results, EEG data,
demographic and behavioral parameters (gender, age, SES, diag-
noses, scores on rating scales), or a combination of these variables
(Barkley, 1976; Gray and Kagan, 2000; Chabot et al., 1999; Barkley
et al., 1991; Hale et al., 2011; Tannock et al., 1995). The predictive
power of neuropsychological tests is considered modest
(Fernandez-Jaen et al., 2008; Nichols and Waschbusch, 2004;
Riccio et al., 2001; Coghill et al., 2007; Ogrim et al., 2014).
EEG-based measures have been used as predictors of response
to stimulants. A 2005 review (Hermens et al., 2005) identified a
combination of behavioral and electrophysiological parameters as
the most promising approach. Several cognitive ERP components,
such as the P3 component following cues (cueP3), targets (P3go/
P3b), no-go signals (P3no-go), contingent negative variation
(CNV), and N2no-go are frequently found to differ between ADHD
subjects and healthy controls (Sangal and Sangal, 2006; Johnstone
et al., 2013; Brandeis et al., 2002). Some of these components, par-
ticularly the P3b, have been investigated as predictors of stimulant
medication response (Chabot et al., 1999; Sangal and Sangal, 2004).
The P3b component has a parietal distribution, however, and most
functional imaging studies indicate MPH effects primarily in
frontal regions (Rubia et al., 2014). Investigating the predictive
power of more anteriorly distributed components such as CNV,
N2no-go, and P3no-go could therefore prove particularly fruitful.
We previously found that whereas non-REs showed deviations in
the parietally distributed cue-P3 compared with healthy controls,
medication responders deviated in the more frontally distributed
P3no-go and CNV components (Ogrim et al., 2014).
We are aware of only one study (Young et al., 1995) examining
changes in ERP components induced by a single dose of MPH as a
basis for predicting clinical response to stimulants in children with
ADHD. The children whose P3b amplitude from an auditory odd-
ball paradigm increased by >30% on a single dose were classified
as REs six months later with an accuracy of 81%. That study was
based on a relatively small group (N = 35), with about an equal
number of REs and non-REs. Our study examines changes causedby a single dose of stimulant medication in a larger group of ADHD
subjects and includes behavioral variables and more frontally dis-
tributed ERP components.
1.2. Considerations in predicting medication response
There are many obstacles in identifying powerful predictors of
medication response. First, one must consider inclusion and exclu-
sion criteria. Most ADHD patients have comorbid disorders, and
studies aimed at finding predictors of clinical use should include
all ADHD patients. The proportion of REs vs. non-REs should be
proximal to the reported prevalence in population studies (about
70–80% REs), as changes in base rate will affect the accuracy of
the predictive model.
Second, there is still no consensus regarding how best to oper-
ationalize the criterion variable of treatment response. Behavior
ratings from parents and teachers are frequently used as outcome
measures, but are criticized for being vulnerable to placebo and
source effects (Ogrim et al., 2014; Herrerias et al., 2001). Gathering
information from several sources and using both standardized and
unstructured methods can counteract some of these problems
while also maintaining the desired ecological validity when evalu-
ating the participants’ day-to-day functioning prior to and during
stimulant medication try-out.
Third, one must consider the number of predictor variables to
include in a model. Previous studies indicate the necessity of more
than one (Hermens et al., 2005), yet there should be as few predic-
tors as possible. Increasing the number of predictors increases the
risk of model overfitting, thereby limiting generalizability. Some
studies have suggested that the number of predictor variables in
the model should be less than 1 per 10 subjects having the least
common outcome (Peduzzi et al., 1996), although simulation stud-
ies indicate that this criterion may be somewhat strict (Vittinghoff
and McCulloch, 2007). Collection of predictor data should also not
be overly demanding of resources or time for patients and their
families.
Finally, it should be considered that the base rate of REs relative
to non-REs in the ADHD population (approximately 70% and 30%,
respectively) itself provides a predictive model with 70% accuracy,
which correctly classifies all REs and misses all non-REs. Curiously,
this aspect is not always considered in the published literature. To
be useful, a predictive model must have significantly higher accu-
racy than the base rate model and provide a means of detecting
non-REs who will be in need of other types of treatment.
1.3. Study aims and hypotheses
We investigated whether effects of a single dose of stimulant
medication in 87 ADHD patients (27 girls; 73 medication-naïve)
aged 8–18 years could predict clinical medication response after
a four-week medication trial. The study included four behavioral
variables (reaction time [RT], RT variability [RTvar], omission
errors, commission errors) and five ERP component amplitudes
(cue-P3, CNV, P3go, N2no-go, P3no-go) that have been found to dif-
fer between ADHD subjects and healthy controls. By investigating
the predictive power of single-dose changes in a combination of
ERP and behavioral variables, this study represents a new approach
in the search for clinically useful predictors of response to stimu-
lants in ADHD.
We hypothesized that ERPs and behavioral variables that have
previously been found to differ in children with ADHD compared
with healthy controls would also be affected by a dose of stimulant
medication, reflecting an improvement towards normalization. We
hypothesized that these effects would be specific to the REs, and
that the non-REs would show smaller effects, thus making the
magnitude of single dose effects predictive of later classification.
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the investigated variables have not been investigated before. The
study was therefore partly exploratory in nature, and the predic-
tive power of the different variables was investigated individually
before variables found to be significantly different in REs and non-
REs were entered into a hierarchical logistic regression analysis. To
avoid model over fitting, the first block of the logistic regression
analysis only contained the two variables that most strongly differ-
entiated REs from non-REs and background variables differing sig-
nificantly between the groups.
To compare the results with prediction based on baseline data,
regression was also performed on results from the baseline test.
We hypothesized that a model based on single-dose effects would
result in higher accuracy of prediction than would prediction based
on baseline data.
2. Methods
2.1. Participants and diagnostic procedures
A neuropsychiatric team comprising two neuropsychologists, a
pediatrician, and a specialist in school psychology, all with several
decades of clinical experience, diagnosed 87 patients with ADHD in
accordance with DSM-IV. Patients with IQs below 70 or diagnosed
brain injury were excluded. Common comorbidities, like behav-
ioral and emotional disorders, learning disabilities, or autism spec-
trum disorders were included. Diagnoses were based on medical
history, clinical interviews [DAWBA (Goodman et al., 2000) or
Kiddie-SADS (Kaufman et al., 2009)], rating scales from parents,
teachers and patients over 12 years, observations and school
reports. One or more of the following scales were applied: Conners’
rating scale revised/Conners3 (Conners, 2008), Behavior Rating
Inventory of Executive Function (BRIEF; Gioia and Isquith, 2000),
the Five to Fifteen questionnaire (FTF – 5–15, Lambek and
Trillingsgaard, 2015). School reports described academic and psy-
chosocial functioning.
After a diagnosis of ADHD was established, the patients and
their parents were informed about and offered participation in
the study, which consisted of two ERP registrations, once without
and once on a single dose of stimulant medication, followed by a
four-week medication trial. A flow chart illustrating the timing of
the different procedures is shown in Fig. 1. The Regional Commit-
tee for Medical Research Ethics approved the project. Eleven cases
were excluded because of the technical quality of the recordings
and one case for non-compliance.
2.2. Assessment of ERPs
EEG was recorded using a Mitsar 201 19-channel EEG system
(http://www.mitsar-medical.com) during a 20-min cued go/no-go
task. The task consisted of 400 pairs of images presented for
100 ms, with 1100-ms inter-stimulus intervals between the onset
of the cue and the onset of the imperative stimulus, andFig. 1. Timing of proced3000-ms inter-trial intervals. Participants were instructed to press
the left mouse button as quickly as possible, but only when the two
paired images were animals (A–A: go)—not ‘‘animal-plant” (A–P:
no-go), ‘‘plant-human,” or ‘‘plant-plant” (100 pairs in each
category). Correct responses had to occur within 200–1000 ms
after presentation of the imperative stimulus. Failure to respond
to A–A pairs within this time interval was considered omission
errors, and responses within this time interval for A–P pairs were
considered commission errors.
Input signals were referenced to earlobe electrodes, filtered
between 0.5 Hz and 50 Hz, and digitized at a sampling rate of
250 Hz, with impedance kept below 5 kX for all 19 electrodes.
An electrode cap with tin electrodes (Electro-cap International,
Eaton OH, USA) was applied with electrodes placed in accordance
with the international 10–20 system at sites Fz, Cz, Pz, Fp1/2,
F3/4, F7/8, T3/4, T5/6, C3/4, P3/4, and O1/2. The EEG data were
re-referenced offline to the common average montage prior to data
processing, and eye blink artifacts were corrected by zeroing the
activation curves of individual independent components corre-
sponding to eye blinks (Jung et al., 2000; Vigario, 1997). Epochs
of the filtered EEG with excessive amplitude (100 lV) and/or
excessively fast (35 lV in 20–35 Hz band) and slow (50 lV in 0–
1 Hz band) frequency activities were automatically marked and
excluded from analysis.
ERPs were registered twice—first without medication (test 1;
T1) and later with a single dose of MPH (N = 79) or DEX (N = 8) (test
2; T2). As the study was conducted in a natural clinical setting,
there was substantial variation in the time interval between the
two tests (1–45 weeks), although the majority of participants com-
pleted T2 within 12 weeks from T1. The reasons for some partici-
pants having particularly long time intervals between tests, was
that T2 was always conducted at the onset of the participant’s clin-
ical medication try out, whereas T1 was conducted at the point in
time when the participant was first offered a try out of stimulant
medication. The reasons for postponement of the try out were
mixed; change of school, moving to a new district, a wish to post-
pone the medication trial from late spring till autumn, parents
needing time to consider the medication offer etc. Using Chi-
Square, we compared the distribution of REs and non-REs in partic-
ipants completing T2 within 12 weeks after T1 (N = 65) with those
(N = 22) completing T2 more than 12 weeks after T1.
ERPs were computed by averaging the remaining trials after
correction and rejection of artifacts. For REs in T1, the mean num-
ber of correct trials after artifact rejection was 151 (SD = 34) in the
cue-condition (all trials with A as the first stimulus), 66 (SD = 23) in
the go condition, and 66 (SD = 18) in the no-go condition. For the
non-REs, the mean number of trials was 159 (SD = 35) in the
cue-condition, 74 (SD = 18) in the go, and 75 (SD = 21) in the no-
go condition.
For REs in T2, the mean number of correct trials after artifact
rejection was 166 (SD = 33) in the cue-condition, 77 (SD = 16) in
the go condition, and 82 (SD = 18) in the no-go condition. For the
non-REs, the mean number of trials was 156 (SD = 40) in theures in the study.
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The amplitudes were measured at the midline electrodes where
the component was observed to be present in the grand mean ERPs
of the groups. The component amplitudes were measured at the
following electrodes and within the following time intervals: ERPs
after stimulus 1; cue-P3, at Pz (270 ms – 370 ms); CNV at Fz, Cz, Pz
(1000 ms–1100 ms). ERPs after stimulus 2: P3go at Pz (260 ms–
400 ms); N2no-go at Fz and Cz (220 ms–330 ms); P3no-go at Fz,
Cz, Pz (300 ms–500 ms). The CNV component, which is a slow fluc-
tuation with largest amplitude immediately preceding the impera-
tive stimulus, was measured automatically as the mean amplitude
the last 100 ms before presentation of the second stimulus in the
cue condition. All other component amplitudes were measured
manually as the local peak amplitude within a pre-defined time
interval based on the onset and offset of the component in the
grand mean ERP waveform collapsed across groups (RE/non-RE)
and tests (T1/T2). The local peak amplitude refers to the point
within the defined time window for the component of interest
with the largest amplitude which is surrounded on both sides by
lower voltages, thereby avoiding measuring the offset of preceding
or onset of following components (Luck, 2014). As the WinEEG
software does not contain an algorithm for automatically exporting
local peak amplitudes, ERP component amplitudes were measured
manually by two of the authors (JFB and IEA), blinded to RE vs.
non-RE classification.
2.3. Medication procedure and criteria for classification of response
The participants had all been diagnosed with ADHD, and were
offered a systematic trial on stimulant medication lasting at least
4 weeks. Both ERP registrations (T1 and T2) were completed before
the 4-week trial, and took place in the same office at approximately
the same time of day. For the single dose test, 54 participants
received 10 mg MPH, 25 received 15 mg MPH, and 8 participants
received 7.5 mg DEX. Those who received 15 mg MPH were
14 years or older, without comorbid anxiety disorders and were
not small for their age. Those who received DEX had experienced
side-effects or made no clinical gains on previous MPH trials.
The standard procedure for the 4-week trial was single tablets
of MPH, titrated from 5 mg  1 per day, up to 20 mg  3 per day.
Doses were not increased to maximum if side-effects occurred
for more than one or two days, or if clinical effects were clearly
seen on lower doses. Daily ratings of ADHD symptoms were com-
pleted by parents and teachers before onset of the trial period and
during the 4 weeks. They were all informed that these ratings were
performed to evaluate effects of the medication try out. Teachers
were not informed about doses or titration. Children over 9 years
of age were encouraged to complete daily self-ratings. Some of
the parents and teachers completed daily 4-point ratings of the
18 ADHD symptoms in the DSM-IV. In other cases, abbreviated
forms asking for comparisons with the period before onset of med-
ication (better, as usual, or worse) were used. Similarly, the chil-
dren were asked to evaluate their attention, behavior, and
feelings, as better, worse, or the same, compared with the period
before onset of medication. Daily ratings were used to capture
more of the variation of functioning than weekly ratings do. In
most cases, parents and children completed a side-effects ques-
tionnaire together once a week, the first time before onset of the
medication trial. The parents were invited to contact the clinic
with any questions they might have during this period.
At the end of the 4-week try out, meetings with parents, teach-
ers, and patients over the age of 12 were arranged. The participants
were asked to tell us about the 4-week period. Had they experi-
enced positive or negative changes? What were the effects of
increasing doses? Did anything change? They were also asked todescribe any side-effects. A previous paper (Ogrim et al., 2014)
describes the reported positive effects.
All important information, from scales, tests, meetings and
phone calls, was registered in the patients’ medical records. The
first author and a team psychologist not involved in the research
independently evaluated this information, which did not include
ERPs or other data from the cued go/no-go task. The following
scores regarding clinical effects were assigned. Score 1 (RE): Posi-
tive changes in core ADHD symptoms reported from at least two
informants (parent, teacher, self) and a joint decision to continue
medication. Score 0 (non-RE): Significant clinical changes in core
symptoms were not seen, or negative effects on these symptoms
were reported. Medication with MPH or DEX was discontinued,
sometimes after a few weeks of prolonged trial. The cases falling
in between these two scores were classified to the score that over-
all best described the available information. Inter-rater agreement
was 80% before consensus discussions. The cases where the raters
differed in classifications were primarily cases where parents and
teachers differed in their opinions, and cases with only modest
gains.
2.4. Variables in the model
The two groups were compared for changes in behavioral vari-
ables in the cued go/no-go task (omission errors, commission
errors, RT, and RTvar), and amplitudes of the ERP components
cue-P3, CNV, P3go, N2no-go, and P3no-go. To control for back-
ground and possible confounding variables differing between REs
and non-REs, the groups were also compared in terms of age, gen-
der, time between the two tests (<12 weeks vs. >12 weeks), sub-
types of ADHD, the presence of comorbid disorders, and IQ.
Background or confounding variables that significantly differed
between REs and non-REs were controlled for in the logistic regres-
sion analysis.
2.5. Statistical methods
To check the group differences in possible confounding vari-
ables, Chi-Squares were applied for dichotomous variables and
independent-samples t-tests for continuous variables.
To identify behavioral variables and ERP components associated
with clinical outcomes, we compared the effects of a single dose of
MPH or DEX with the same variables as measured without medica-
tion by subtracting the two values (T2–T1). These difference scores
were compared in REs vs. non-REs using independent samples t-
tests for behavioral data. For the ERP component amplitudes, these
differences were assessed using multivariate analyses of variances
(MANOVA). The MANOVAs included electrode site and medication
(T1 vs. T2) as within-subjects factors, and group (RE vs. non-RE) as
a between-subjects factor. We performed multivariate analyses
rather than traditional repeated-measures ANOVA, as the multi-
variate model does not assume sphericity—an assumption often
violated by psychophysiological data (Picton et al., 2000). Post-
hoc analyses were conducted using the Bonferroni correction. Cor-
rected p-values are reported.
Variables that were differentially affected by stimulant medica-
tion in REs and non-REs were included in a hierarchical logistic
regression analysis. To reduce the risk of bias (Peduzzi et al.,
1996), only the two ERP or behavioral variables showing the lar-
gest effect sizes in differentiating medication effects in REs and
non-REs were included in the first step. Background variables that
differed significantly between the groups were also included in the
first step to control for the possibly confounding effects of these
variables. In the second step, the remaining ERP and behavioral
variables that were significantly different in REs and non-REs were
included to investigate if significant gains could be achieved by
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dose changes with predictions based on results for REs and non-
REs at baseline, we also performed a regression analysis using
the data from the baseline ERP registration only.
Statistical analyses were performed using SPSS Vol. 21 (http://
www.spss.com) and STATA 14.1 (http://stata.com), with alpha
level set at .05. Cohen’s d effect sizes were calculated with correc-
tion for different sample sizes.
3. Results
As shown in Table 1, neither time interval between tests
(<12 weeks vs. >12 weeks) nor type of medication (MPH vs. DEX)
differed significantly between REs and non-REs. No significant
between-groups differences were found for subtype of ADHD,
comorbid disorders, or gender. The mean age in the REs was
1.2 years younger than in the non-REs (p = .04). Age was therefore
controlled for in the regression analysis. The non-RE group scored a
mean of 8 IQ points lower than REs (p = .03). IQ data were unavail-
able for 13 patients, however, and was therefore not controlled for
in the regression analysis.
Table 2 outlines the descriptive statistics and summary of the
MANOVA interaction effects involving group and medication
effects on ERP component amplitudes. There were no significant
group differences in effects of stimulant medication on the N2no-
go or P3go.
A significant group by medication interaction for the cue-P3
was found (p < .001 d = 0.90). The effect of a single dose of medica-
tion resulted in no significant change in the REs (mean differ-
ence = 0.53 lV, p = .134), but a significant decrease in amplitude
in the non-REs (mean difference = 1.48 lV, p = .006). A significant
three-way interaction was found for the CNV, with the effect of a
single dose of medication differing significantly between groups
only at Cz (p = .004, d = 0.79): Non-REs demonstrated a significant
decrease in CNV amplitude on a single dose of medication com-
pared with baseline (mean difference = 0.80 lV, p < .018), and REs
showed a marginally significant increase (mean differ-
ence = 0.51 lV, p = .051).
A significant three-way interaction was found for the P3no-go:
The single dose effect was significantly different between groups atTable 1
Potential confounders.
Variable (Total N = 87) Responders (REs N = 62)
Age M = 12.1 (SD = 2.5)
Total IQ M = 96 (SD = 15)
Male (N = 60) 42
Female (N = 27) 20
ADHD-C (N = 54) 40
ADHD-I (N = 33) 22
ODD/CD (N = 29) 23
Anxiety/depression (N = 24) 17
Learning disabilities (N = 42) 32
High-functioning autism (N = 10) 6
Other disorders (N = 15) 8
Test interval <12 weeks (N = 65) 44
Test interval >12 weeks (N = 22) 18
Methylphenidate (N = 79) 56
Dexamphetamine (N = 8) 6
IQ: Intelligence quotient. M: Mean. SD: Standard Deviation. ADHD-C / AD
Inattentive type. ODD: Oppositional defiant disorder. CD: Conduct disorder
LD, IQ between 70 and 80, and a need for broad educational support; (b)
dyscalculia). Other disorders included Reactive attachment disorder and T
* p < .05.both Cz (p < .001, d = 1.76) and Pz (p < .001, d = 1.11), but not at Fz.
Pairwise comparisons of the P3no-go amplitude at Cz revealed a
significantly larger amplitude on a single dose of medication com-
pared with baseline in REs (mean difference = 4.27 lV, p < .001)
and significantly smaller P3no-go amplitudes on a single dose of
medication compared with baseline for non-REs (mean differ-
ence = 1.80 lV, p = .031). Based on the MANOVA results, changes
in cue-P3 amplitude at Pz, and changes in CNV and P3no-go ampli-
tudes at Cz were included in the regression analysis. The grand
mean ERPs from the cue, go and no-go conditions at T1 and T2 in
the REs and non-REs can be seen in Fig. 2.
The changes in 3 of the 4 behavioral variables were significantly
different in REs and non-REs: RT [p < .001, d = 0.95], RTvar
[p < .001, d = 0.87], omission errors [p < .001, d = 0.96]). The
descriptive statistics for the behavioral data are shown in Table 3.
3.1. Logistic regression analysis
A hierarchical logistic regression analysis was conducted to pre-
dict clinical medication response. Of the six ERP or behavioral vari-
ables showing differential effects of medication in REs and non-
REs, changes in P3no-go amplitude and omission errors showed
the largest effect sizes and were included in the first block of the
analysis. To control for the age differences between the RE and
non-RE groups, age was also included in this step. To investigate
whether the addition of other factors would contribute signifi-
cantly to prediction, the second block of the analysis also included
the remaining four variables that individually differed between REs
and non-REs.
A test of block 1 against a constant-only model was statistically
significant, indicating that the predictor set was more accurate in
predicting medication response than a model predicting that all
participants would belong to the most prevalent category (REs)
(v2 = 54.55, p < .001, df = 3). Nagelkerke’s R2 of .667 indicated a
moderately strong relationship between prediction and grouping.
When setting the criterion for classification at .50 (predicting that
a participant was an RE if the predicted probability of response was
>50%, and a non-RE if <50%), the model had an overall accuracy of
86.2%, correctly classifying 56 of the 62 REs (sensitivity = 90.3%),
and 19 of the 25 non-REs (specificity = 76.0%). Prediction ofNon-responders (non-REs N = 25) Difference
M = 13.3 (SD = 2.7) p = 0.04*
M = 87 (SD = 15) p = 0.05*
18 NS (p = 0.70)
7
14 NS (p = 0.62)
11
6 NS (p = 0.36)
7 NS (p = 1.00)
10 NS (p = 0.46)
4 NS (p = 0.64)
7 NS (p = 0.17)
21 NS (p = 0.32)
4
23 NS (p = 1.00)
2
HD-I: Attention deficit hyperactivity disorder. C: combined type. I:
. Learning disabilities (LD): a broad category consisting of (a) General
Specific LD: IQ above 80, circumscribed educational needs (dyslexia,
ourette’s syndrome. Significant differences are marked by ⁄.
Table 2
Medication induced changes in ERP component amplitudes.
Responder (n = 62) Non-responder (n = 25) Group medication Group medication  electrode
Baseline (T1) Medication (T2) Difference (T2–T1) Baseline (T1) Medication (T2) Difference (T2–T1) df F p df F p
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Cue-P3 1.85 14.44*** <.001
Pz 4.32 (3.4) 4.85 (3.6) 0.53 (2.2) 5.20 (3.4) 3.72 (2.5) 1.48 (2.2)
CNV 1.85 8.63** .004 2.84 3.54* .033
Fz 1.86 (2.3) 1.82 (2.1) 0.04 (1.7) 1.54 (1.8) 1.93 (1.9) 0.39 (1.9)
Cz 0.55 (1.7) 1.06 (1.7) 0.51 (1.8) 1.41 (1.6) 0.61 (1.8) 0.80 (1.4)
Pz 1.84 (1.8) 1.66 (2.0) 0.18 (1.7) 1.64 (1.6) 1.10 (1.6) 0.54 (1.5)
P3go 1.85 2.62 .109
Pz 9.20 (4.4) 9.43 (4.6) 0.23 (3.9) 9.38 (3.9) 8.20 (3.9) 1.18 (2.9)
N2no-go 1.85 3.54 .063 1.85 2.66 .107
Fz 7.84 (4.3) 8.81 (4.6) 0.97 (3.5) 7.32 (5.3) 8.75 (4.3) 1.42 (3.7)
Cz 5.33 (3.8) 4.96 (3.7) 0.36 (3.2) 2.55 (4.8) 4.10 (5.5) 1.55 (2.1)
P3no-go 1.85 49.22*** <.001 2.84 13.71*** <.001
Fz 1.10 (3.6) 1.48 (4.8) 0.38 (3.8) 1.09 (3.7) 0.27 (3.2) 0.82 (3.3)
Cz 4.74 (4.4) 9.01 (4.6) 4.27 (3.5) 8.44 (5.6) 6.64 (5.5) 1.80 (3.4)
Pz 5.91 (4.1) 7.70 (4.6) 1.79 (3.3) 6.74 (3.9) 5.06 (3.5) 1.68 (2.6)
Note:Means and SDs of the ERP component amplitudes at baseline (T1) and on stimulant medication (T2) in the responder and non-responder groups, and tests of significant differences in medication effects (ANOVA) between the
groups. Significant differences are marked by ⁄.
* p < .05.
** p < .01.
*** p < .001.
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Fig. 2. Grand mean ERPs from the responders (REs) and non-responders (non-REs) at baseline (T1; gray lines) and on a single-dose of stimulant medication (T2; black lines).
The time-intervals within which individual peak amplitudes for the different ERP components were scored are marked by gray boxes.
Table 3
Medication induced changes in behavioral variables.
RE (n = 62) Non-RE (n = 25) Difference
T1 M (SD) T2 M (SD) Diff. M (SD) T1 M (SD) T2 M (SD) Diff. M (SD) df t p d
Omissions 15.63 (14.2) 5.29 (5.6) 10.34 (11.6) 8.04 (9.0) 7.76 (13.0) 0.28 (6.9) 85 4.98*** <.001 0.96
Commissions 5.84 (7.2) 3.31 (4.8) 2.53 (6.5) 5.56 (9.3) 2.60 (5.0) 2.96 (5.0) 85 0.30 .768 0.07
RT 428.8 (76.0) 396.6 (71.7) 32.2 (51.1) 397.6 (57.9) 414.4 (66.6) 16.8 (52.4) 85 4.02*** <.001 0.95
RT variability 15.30 (4.4) 10.98 (3.4) 4.32 (4.3) 13.10 (3.9) 12.20 (3.1) 0.90 (2.9) 85 3.65*** <.001 0.86
Note: Means and SDs of behavior variables at baseline (T1) and on stimulant medication (T2) in the responder (RE) and non-responder (non-RE) groups, and independent
samples t-tests of the differences in medication effects (T2–T1) between the groups.
Significant differences are marked by ⁄.
*** p < .001.
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Fig. 3. The grand mean P3no-go component at Cz in the responders (REs) and non-responders (non-REs) at baseline (T1; gray lines) and on a single-dose of stimulant
medication (T2; black lines). The scatter plot shows the P3no-go amplitudes at T1 and T2 in each individual participant.
Table 4
Results of the logistic regression analysis.
B SE Wald p Odds ratio (eB)
D P3 no-go (Cz) 0.58 0.16 13.59 <.001 1.79
D Omission 0.10 0.07 2.50 .114 0.93
Age 0.39 0.17 5.60 .018 0.68
Constant 4.87 2.10 5.37 .021 130.25
Note: Summary of results from block 1 in the logistic regression analysis.
3284 G. Ogrim et al. / Clinical Neurophysiology 127 (2016) 3277–3287response was correct in 56 of 62 cases (positive predictive
power = 90.3%), and prediction of non-response was correct in 19
of 25 cases (negative predictive power = 76.0%). The Wald criterion
demonstrated that only the change in P3no-go amplitude (p < .001)
and age (p < .018) contributed significantly to prediction. Fig. 3
shows the increase in the P3no-go component in REs and the
decrease in non-REs, as well as the P3no-go amplitudes at T1 andFig. 4. Illustration of the regression model using changes in P3no-go amplitude, chang
predictive margins and 95% confidence intervals (CI) for different changes in P3 no-go a
classification criteria, respectively.T2 for all individual participants. A summary of the results from
block 1 can be found in Table 4.
Block 2, which, in addition to the variables in block 1, also
included changes in cue-P3 at Pz, changes in CNV at Cz, changes
in RT and changes in RTvar, did not significantly improve the pre-
diction compared with the variables in block 1 only (v2 = 7.85,
p = .097, df = 4).
In a clinical setting, one might want to make the classification
criterion stricter than .50 to ensure that as few non-REs as possible
are wrongly predicted to be REs. Adjusting the classification crite-
rion to .70 for block 1 (predicting that a participant was an RE if the
predicted probability was >70%, and a non-RE if <70%), resulted in
an overall accuracy of 83.9%, correctly classifying 51 of the 62 REs
(sensitivity = 82.3%), and 22 of the 25 non-REs (specificity = 88.0%).
Prediction of response was correct in 51 of 54 cases (positive pre-
dictive power = 94.4%), and prediction of non-response was correct
in 22 of 33 cases (negative predictive power = 66.7%). Although thises in the number of omission errors, and the age of participants as predictors. The
mplitude at ages 8, 12 and 16 are shown. The horizontal lines show the .50 and .70
G. Ogrim et al. / Clinical Neurophysiology 127 (2016) 3277–3287 3285model with a .70 classification criterion wrongly classifies a few
more REs than the .50 cut, the model now only missed 3 partici-
pants later classified as non-REs. Fig. 4 illustrates the predicted
probability of belonging to the RE group for different changes in
P3no-go amplitude at ages 8, 12 and 16. The black and red horizon-
tal lines show the .50 and .70 classification criteria, respectively.
Another analysis, not considering age, converted the difference
scores (T2–T1) on P3no-go to z-scores and further into quartiles.
Patients with a reduction in P3 no-go amplitude of 0.5 mv or more
belong to Quartile Group 1 (Q1) with only 25% probability of a pos-
itive response. Q4 comprised of patients who increased their P3
no-go amplitude 5.3 mv or more. In this group the probability of
being a responder was 100%.3.2. Regression analysis at baseline
At baseline (T1), the REs and non-REs differed significantly only
on the P3no-go amplitude (p = .002, d = 0.77), omission errors
(p = .004, d = 0.59) and CNV amplitude (p = .033, d = 0.53). Again,
the P3no-go amplitude and omission errors were the variables that
most strongly differed between REs and non-REs. Again, a hierar-
chical logistic regression was performed. The first block only con-
tained age, with P3no-go amplitude and omission errors being
added in the second block, and CNV amplitude in the third block.
The results showed that the second block was significantly better
at predicting medication response than the first block alone
(v2 = 13.31, p = .001, df = 2). The third block did not improve pre-
diction significantly (v2 = 0.07, p = .795, df = 1). In the second block,
only P3no-go amplitude contributed significantly to the prediction
(p = .014). This T1-model did, however, have lower accuracy of pre-
diction at the .50 classification criterion (75.9%) than the single-
dose effect model, correctly predicting 56 of the 62 (90.3%) REs,
and 10 of the 25 (40.0%) non-REs.4. Discussion
A single dose of stimulant medication resulted in a number of
differing effects in REs and non-REs in this study. REs had signifi-
cantly larger reductions in RT, RT variability, and omission errors
and larger increases in the amplitudes of the P3no-go and CNV
component amplitudes compared with non-REs. Whereas P3no-
go and CNV amplitudes increased in REs, significant amplitude
reductions were unexpectedly observed in non-REs. Also, whereas
the cue-P3 amplitude did not change significantly in the REs, the
non-REs demonstrated a significant amplitude reduction on a sin-
gle dose of medication. These results indicate the effects of stimu-
lant medication are not only absent or reduced in non-REs, but
may actually have negative effects in some individuals. Changes
in P3no-go amplitude followed by the changes in the number of
omissions errors best differentiated REs from non-REs.
The base rate of medication response in the present sample was
71.3%. A logistic regression model using changes in P3no-go ampli-
tude and omission errors as predictors, and controlling for the age
of the participants, significantly improved the prediction. When
predicting that all participants with a predicted probability of
medication response above .50 would be later classified as REs, this
model had an overall accuracy of 86.2%. This model correctly iden-
tified 90.3% of the REs and 76.0% of the non-REs. When increasing
the criterion for predicting that a participant would belong to the
RE group to .70 probability of response, the number of non-REs
classified correctly increased to 88.0%. Adding the other variables
that independently differed between the REs and non-REs did
not significantly improve the prediction.
To illustrate the results, Fig. 4 shows the predicted probability
of belonging to the RE group for different changes in P3no-goamplitude at ages 8, 12 and 16. The horizontal lines show the .50
and .70 classification criteria, respectively. The choice of where to
place the classification criterion will depend on whether one deci-
des that it is of higher importance to identify all non-REs at the cost
of also misclassifying some REs, or whether one accepts missing
more of the non-REs to avoid misclassifying REs. If the aim of pre-
diction is to monitor potential non-REs to enable quick initiation of
alternative treatment options, the .70 criterion will identify most
of the non-REs and imply monitoring 38% of the participants. Set-
ting the criterion at .50 would reduce the number of individuals
monitored to 29% of the participants, thus saving some resources
by not monitoring as many who are later classified as REs, at the
cost of missing more of the non-REs. As can be seen from Fig. 4,
the predicted probability of medication response is high in partic-
ipants with large increments in P3no-go amplitude at all ages, and
the confidence intervals are relatively narrow, indicating that the
prediction for these individuals can be made with high accuracy.
When P3no-go amplitude changes are small or negative, the prob-
ability of medication response is lower in older than in younger
participants. Also, the confidence intervals increase when changes
in P3no-go amplitudes are small or negative, making the estimated
probabilities more uncertain.
Only one previous study (Young et al., 1995) has attempted to
use ERP changes induced by a single dose of stimulants to predict
real-life medication effects: It found an 81% accuracy of prediction
using changes in the P3b component amplitude from an auditory
oddball task as a predictor variable. Our study did not find signifi-
cant group differences in stimulant effects on the parietal P3go
amplitude; which is an equivalent to the P3b from an oddball task,
although the somewhat similar cue-P3 amplitude was significantly
reduced on a single dose of medication in the non-REs. The group
differences in single dose effects on the more frontally distributed
P3no-go component were, however, much larger. This finding is in
line with previous functional imaging studies demonstrating that
MPH acts primarily by enhancing activation in fronto-striatal areas
(Rubia et al., 2014; Czerniak et al., 2013), areas that have also been
indicated as involved in generation of the P3no-go component (see
review by Huster et al., 2013).
4.1. Increasing detectability using single-dose administration
Several studies varying in patient selection and treatment
response evaluation have attempted to predict response to stimu-
lant medication based on behavioral and/or electrophysiological
markers before initiation of medication trials (Hermens et al.,
2006; Rubia et al., 2014; Chabot et al., 1999; Ogrim et al., 2014;
Johnstone et al., 2013; Czerniak et al., 2013; Linssen et al., 2012,
2011). The easiest, most valid evaluation of improved predictive
power as a result of supplementing baseline assessment with
assessment on medication is therefore to compare these results
with prediction based on baseline assessment, using the same sub-
jects and variables. The variables significantly differentiating REs
from non-REs were fewer at baseline (T1) than when investigating
the single dose induced changes. Again, P3no-go amplitude and
omission errors showed the largest effects. A regression based on
P3no-go amplitude and omission errors at baseline (T1), again con-
trolling for the age of the participants, was significantly better than
diagnosis alone at predicting later classification. The T1 model did
not, however, perform as well as the model using the effects of a
single dose of medication as a basis for prediction. In this study,
the difference scores used were computed by simply subtracting
raw scores at T2 from raw scores at T1, without controlling for
group differences at T1. Some variance due to group differences
at T1 was thereby maintained in the difference scores, which, in
this case, captured more of the differences between the REs and
non-REs than baseline scores alone or difference scores controlled
3286 G. Ogrim et al. / Clinical Neurophysiology 127 (2016) 3277–3287for baseline differences. Our results therefore indicate that both
baseline differences and the effects of stimulant medication con-
tribute to predicting medication response, and that prediction
based on ERP and behavioral data can be improved substantially
by making two assessments—baseline and single dose.
4.2. Cognitive processes modulated by stimulant medication
The exact cognitive processes reflected in the P3no-go compo-
nent are still debated. Most studies describe P3no-go as an index
of inhibition, despite limited support for this hypothesis (Huster
et al., 2013). Support is stronger for interpreting P3no-go as reflect-
ing a monitoring process. Using independent component analysis,
two overlapping and functionally different subcomponents of
P3no-go have been identified (Brunner et al., 2015). There is accu-
mulating evidence that the target-related P3b reflects reactivation
of a prepared and well-established stimulus–response link
(Verleger et al., 2005, 2015). In contrast, the P3no-go subcompo-
nent with the shortest latency is thought to reflect activation of
an unprepared stimulus– (non-) response link (Aasen and
Brunner, 2016). This activation of a sub-dominant stimulus–re-
sponse link is slower and requires a higher degree of voluntary
control and greater effort (energization) than does implementing
prepared actions. The second subcomponent may reflect the pro-
posed monitoring process.
This understanding of P3no-go indicates that the core deficit
being improved by stimulant medication in REs may not be inhibi-
tion, but rather a problem of initiating appropriate responses
requiring effort, and monitoring the quality of ones task perfor-
mance. In line with this interpretation, the reported benefits of
medication were primarily improved sustained attention and initi-
ation of such appropriate behavior as completing homework,
rather than inhibition in the form of reduced impulsive acts
(Ogrim et al., 2014). To better understand the specific processes
affected by stimulant medication, future studies should investigate
possible differential effects of stimulants on the two subcompo-
nents of P3no-go.
4.3. Limitations and clinical implications
For our findings to be established as a useful clinical method for
predicting stimulant medication response, the results should be
replicated in a double-blinded, placebo-controlled, crossover
study. As this study was conducted in a naturalistic clinical setting,
it has a number of limitations in terms of design. The study did not
have a placebo control condition, and neither participants and their
parents, nor teachers were blinded as to when the active medica-
tion trial was conducted. The participants also knew that they
received medication before the second, but not the first ERP-
registration, making it possible that placebo or nocebo effects
could partly explain the present results, but probably not the dif-
ferences in REs and non-REs. Also, the clinicians evaluating treat-
ment response knew that the participants had been receiving
stimulant medication in the evaluated period. Another limitation
is that the time between the baseline and single dose ERP registra-
tions varied a lot, which could increase error variance due to mat-
urational factors. The timing between the two tests did not differ
between REs and non-REs, however. Also, some of the observed
changes could be due to training rather than single dose effects
as the test on a single dose of medication was systematically con-
ducted after the baseline test. This procedure was the same for
both groups however.
In addition to these limitations, the inter-rater agreement in
terms of medication response was not perfect. Some of the partic-
ipants wrongly classified by the model could therefore be due to
cases where there had been disagreement in the classificationbased on the four-week try out. This limitation, however, is hard
to avoid as there exists no perfect, flawless way of determining
what constitutes a ‘‘real” clinical response to stimulant medication.
Finally, as the number of studies investigating the effects of stim-
ulant medication on ERP components and behavior are limited,
the nature of this study was partially exploratory in nature. The
method of first investigating group differences in the different vari-
ables and then investigating those with the largest group differ-
ences is a method that is more vulnerable to model overfitting
than a model purely based on theory and previous findings. A repli-
cation of the present study using the variables found to be the most
predictive in this study is therefore warranted.
Despite these limitations, the results of this study are highly
promising, providing significantly improved prediction compared
with prediction based on the base rate of responders in ADHD pop-
ulations. To avoid long periods of ineffective treatment with stim-
ulants, it is of great importance to identify quickly the non-REs in
order to find more effective treatment options for them: another
medication and/or psychosocial treatments. Because the mean IQ
of non-REs was 8 points lower than those of the REs, non-RE’s
symptoms may partially reflect inattention and hyperactivity
resulting from etiologies other than those of the REs, including fac-
tors related to learning disabilities and the posterior attention sys-
tem (Posner and Petersen, 1990; Petersen and Posner, 2012).
The data in this study were gathered in a clinic and included
patients with the two main subtypes of ADHD, a broad range of
comorbidities, and IQs as low as 70, excluding only mental retarda-
tion and brain injuries. We believe that our sample resembles the
real-world clinical situation and would argue that the results
reflect an ecologically valid estimation of predictive power.
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